| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.54▲ | 1.55▼ | 1.58▼ | 1.61▼ | 1.31▲ |
| MA10 | 1.54▲ | 1.62▼ | 1.67▼ | 1.40▲ | 1.28▲ |
| MA20 | 1.55▼ | 1.69▼ | 1.76▼ | 1.29▲ | 1.30▲ |
| MA50 | 1.66▼ | 1.71▼ | 1.52▲ | 1.24▲ | 1.53▲ |
| MA100 | 1.74▼ | 1.47▲ | 1.34▲ | 1.30▲ | 2.18▼ |
| MA200 | 1.74▼ | 1.36▲ | 1.31▲ | 1.45▲ | 2.48▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | -0.026▼ | -0.051▼ | 0.056▲ | 0.050▲ |
| RSI | 32.176▼ | 31.905▼ | 40.519▼ | 58.573▲ | 54.526▲ |
| STOCH | 62.500 | 5.556▼ | 5.171▼ | 71.210 | 45.998 |
| WILL %R | -16.667▲ | -90.741▼ | -95.327▼ | -55.556 | -53.571 |
| CCI | 41.252 | -103.221▼ | -133.128▼ | 86.535 | 255.297▲ |
|
Wednesday, September 23, 2020 04:38 AM
This month, we saw the AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) up an impressive 39%. Meanwhile over the last ...
|
|
Tuesday, September 22, 2020 05:30 AM
PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization ...
|
|
Monday, September 21, 2020 01:14 AM
UBS Group AG reduced its stake in shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by 39.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/09/20 | 1.77 | 1.83 | 1.51 | 1.53 | 2,701,542 |
| 22/09/20 | 1.98 | 2.05 | 1.75 | 1.765 | 5,747,608 |
| 21/09/20 | 1.63 | 2.13 | 1.55 | 1.81 | 15,792,143 |
| 18/09/20 | 1.44 | 1.65 | 1.40 | 1.57 | 3,028,540 |
| 17/09/20 | 1.31 | 1.50 | 1.27 | 1.37 | 1,700,000 |
| 16/09/20 | 1.25 | 1.31 | 1.22 | 1.28 | 717,000 |
| 15/09/20 | 1.26 | 1.29 | 1.20 | 1.22 | 484,800 |
| 14/09/20 | 1.12 | 1.29 | 1.11 | 1.26 | 2,272,800 |
| 11/09/20 | 1.15 | 1.15 | 1.05 | 1.07 | 556,130 |
| 10/09/20 | 1.16 | 1.17 | 1.09 | 1.09 | 396,017 |
|
|
||||
|
|
||||
|
|